RESULTS OF THE APPLICATION OF HAEMOPOIETIC GROWTH FACTORS AFTER HIGH DOSE CHEMOTHERAPY WITH TRANSPLANTATION OF HAEMOPOIETIC STEM CELLS
https://doi.org/10.51523/2708-6011.2011-8-4-10
Abstract
The article presents early and long-term results of the combined application of haemopoetic growth factors, i.e. erythropoietin and granulocyte colony-stimulating factor after high-dose chemotherapy with haemopoetic stem cell transplantation in patients with hematologic and oncohematologic disorders. It has been established that the combined therapy with haemopoetic growth factors after the allogeneic transplantation of haemopoetic stem cell leads to better donor marrow engraftment. This reduces the average patients` stay at hospital in the posttransplantation period and increases the indicators of 5-year-old non-relapsing survival rate of patients with Hodzhkin`s lymphoma treated with a combination of erythropoietin and granulocyte colony-stimulating factor.
About the Authors
E. A. Kuzmich
Republican Research Center for Hematology and Transfusiology, Minsk
Belarus
Belarus
V. A. Zmachinskiy
Belarussian Medical Academy for Postgraduate Education, Minsk
Belarus
Belarus
References
1. Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma / R. Abraham [et al.] // Bone Marrow Transplant. - 1999. - Vol. 94. - P. 1291-1297.
2. Regimen-related toxicity in patients undergoing bone marrow transplantation / S. Bearman [et al.] // Journal of Clinical Oncology. - 1988. - Vol. 6. - P. 1562-1568.
3. High dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (> 65 years) myeloma patients: comparison with younger patients treated on the same protocol / E. Jantunen [et al.] // Bone Marrow Transplant. - 2006. - Vol. 107. - P. 917-922.
4. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease / J. A. Glaspy [et al.] // Cancer. - 2003. - Vol. 97. - P. 1312-1320.
5. Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha / M. McColl [et al.] // J. Exp. Med. - 1992. - Vol. 176. - P. 593-598.
6. Белогурова, М. Б. Клиническое использование гемопоэтических ростовых факторов / М. Б. Белогурова // Практическая онкология. - 2003. - Т. 4, № 3 - С. 183-190.
7. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone / N. Flomenberg [et al.] // Blood. - 2005. -Vol. 106. - P. 1867-1874.
8. Pusic, I. The Use of Growth Factors in Hematopoietic Stem Cell Transplantation / I. Pusic, J. F. DiPersio // Current Pharmaceutical Design. - 2008. - Vol. 14. - P. 1950-1961.
9. Addition of erythrpoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hematopoietic progenitor mobilization / A. Olivieri [et al.] // Bone Marrow Transplantation. - 1995. - Vol. 16. - P. 765-770.
10. EPO in combination with G-CSF improves mobilization effectivness after chemotherapy with ifosfamide, epirubicin, and etoposide and reduces costs during mobilization and transplantation of autulogous hematopoietic progenitor cells / C. Hart [et al.] // Bone Marrow Transplantation. - 2009. - Vol. 43(3). - P. 197-206.
11. Kaushansky, K. Lineage-specific hematopoietic growth factors / K. Kaushansky // N Engl J Med. - 2006. - Vol. 354. - P. 2034-2045.
Review
For citations:
Kuzmich E.A., Zmachinskiy V.A. RESULTS OF THE APPLICATION OF HAEMOPOIETIC GROWTH FACTORS AFTER HIGH DOSE CHEMOTHERAPY WITH TRANSPLANTATION OF HAEMOPOIETIC STEM CELLS. Health and Ecology Issues. 2011;(4):62-66. (In Russ.) https://doi.org/10.51523/2708-6011.2011-8-4-10
Views: 247
Email this article 